The DOI matches its Crossref record.
The Pharmacokinetic and Pharmacodynamic Profile of Tigecycline
Open accessAbstract
Tigecycline, a first-in-class expanded-spectrum antimicrobial agent, has demonstrated efficacy in the treatment of complicated intra-abdominal and skin and skin-structure infections. This new antibiotic is available as an intravenous formulation and exhibits linear pharmacokinetics. It is rapidly distributed and has a large volume of distribution, indicating extensive tissue penetration. After a 100-milligram loading dose, followed by 50 milligrams every 12 h, the steady-state maximum concentration in serum after a 1-h infusion is approximately 0.6 microg/mL, the 24-h steady-state area under the concentration-time curve is approximately 5-6 microg.h/mL, and the terminal elimination half-life is approximately 40 h. The major route of elimination of tigecycline is through the feces, primarily as unchanged drug. The pharmacokinetic profile is not affected by severe or end-stage renal disease, nor is it significantly altered by hemodialysis. The pharmacokinetics of tigecycline are also not affected by food, although tolerability is increased if the drug is administered following a meal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Roberts, J. A., Abdul-Aziz, M. H., Lipman, J., Mouton, J. W., Vinks, A. A., Felton, T. W., Hope, W. W., Farkas, A., Neely, M. N., Schentag, J. J., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70036-2 · Cited by 1,046
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Crank, C., & O'Driscoll, T. (2015) · Infection and Drug Resistance · doi:10.2147/idr.s54125 · Cited by 505
Hirsch, E. B., & Tam, V. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq108 · Cited by 477
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., & Ellis-Grosse, E. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl403 · Cited by 304
Self-citationTigecycline: A Critical Analysis
Stein, G. E., & Craig, W. A. (2006) · Clinical Infectious Diseases · doi:10.1086/505494 · Cited by 298
Excess Deaths Associated With Tigecycline After Approval Based on Noninferiority Trials
Prasad, P., Sun, J., Danner, R. L., & Natanson, C. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis270 · Cited by 298
Acinetobacter baumannii: a universal threat to public health?
Giamarellou, H., Antoniadou, A., & Kanellakopoulou, K. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.02.013 · Cited by 258
Structural basis for differential inhibition of eukaryotic ribosomes by tigecycline
Li, X., Wang, M., Denk, T., Buschauer, R., Li, Y., Beckmann, R., & Cheng, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49797-7 · Cited by 21
T cell toxicity induced by tigecycline binding to the mitochondrial ribosome
Shao, Q., Khawaja, A., Nguyen, M. D., Singh, V., Zhang, J., Liu, Y., Nordin, J., Adori, M., Axel Innis, C., Castro Dopico, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59388-9 · Cited by 16
Metadata
- Authors
- Meagher, A. K., Ambrose, P. G., Grasela, T. H., & Ellis‐Grosse, E. J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09
- Volume
- 41
- Issue
- s5
- Pages
- S333-S340
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2106373938
- Cited by
- 188
- References
- 0
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.